| *Sponsored by Nutriband Inc.
Low Float Nasdaq Profile (NTRB) Is Earning Breakout Potential For These 9 Reasons
January 21st Greetings, Friend!
Nutriband Inc. (Nasdaq: NTRB) is a pharmaceutical company climbing my watchlist early in 2025.
Why? Part of its due to its innovative approach to transdermal drug delivery and its potential to revolutionize patient care, particularly in the field of pain management and abuse prevention.
The company's primary focus is on developing a portfolio of transdermal pharmaceutical products, with its flagship product being an abuse-deterrent fent-a-nyl patch incorporating their proprietary AVERSA™ technology.
This technology is designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, addressing a critical issue in the opioid crisis.
Nutriband's potential for growth and market impact is supported by several key factors:
#1. Strong Fi-nan-cial Position: As of October 31, 2024, Nutriband reported cash reserves of $5.7Mn, providing a solid foundation for ongoing development and commercialization efforts.
#2. Revenue Growth: One of the company's subsidiaries has shown significant revenue growth, with a record third quarter in 2024 reporting revenue of $645k+, up 50.94% year-over-year. This growth trend continued from previous years, with a 48% increase in revenue for Q2 2023 compared to Q2 2022.
#3. Market Potential: According to Health Advances' assessment, upon FDA approval, Aversa Fent-a-nyl is expected to reach peak annual sales of $200Mn. If non-abuse-deterrent formulations lose marketing approval, this could potentially increase to over $800Mn in revenue.
#4. Diverse Product Portfolio: Beyond AVERSA™, Nutriband is developing a range of transdermal products for pharmaceuticals with abuse risks and exploring applications for delivering biologics typically administered by injection.
#5. Strategic Partnerships and Distribution: Nutriband's products are being rolled out in prominent retail locations nationwide, including Target, Walmart, Walgreens, and CVS, indicating strong market penetration.
#6. Intellectual Property Protection: The company has been extending its patent protection for AVERSA™ technology, recently securing a patent in Macao, China.
#7. Manufacturing Capabilities: Nutriband owns its manufacturing and clinical development facilities, which significantly reduces costs for AVERSA™ and other technologies.
#8. Potential Upcoming Milestones: Nutriband is targeting an NDA submission for AVERSA™ Fent-a-nyl in the first half of 2025, which could be a significant catalyst for the company.
#9. Low Float: With just over 5Mn shares in its float, the profile has a low float, which could potentially lead to increased volatility in moments.
Nutriband's focus on addressing the opioid crisis through innovative drug delivery systems positions it at the intersection of two critical healthcare trends: the need for effective pain management and the imperative to prevent drug abuse.
The company's AVERSA™ technology has the potential to set a new safety standard for transdermal opioid medications, potentially saving countless lives.
Nutriband's diverse revenue streams from its subsidiaries, growing sales, and strong cash position provide a degree of stability as it pursues its ambitious goals.
As Nutriband approaches key milestones in 2025, particularly the planned NDA submission for AVERSA™ Fent-a-nyl, it represents an intriguing innovator of healthcare solutions with significant market potential.
Coverage is officially initiated on Nutriband Inc. (Nasdaq: NTRB). When updates are available, I'll be in touch.
All the best, Dane James Editor Market Pulse Today
Sources: NTRB Website NTRB Presentation
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, a single member limited liability company. Data is provided from third-party sources and MarketPulseToday is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired by TD Media LLC for a period beginning on 01/21/2025 and ending on 01/22/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid five thousand USD (“Funds”) to disseminate information about (NTRB:US) via digital communications.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (NTRB:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ntrb/
The single member of Thousand Sun Media LLC is also the single member of TD Media LLC.
Pursuant to an agreement between TD Media LLC and Nutriband Inc., TD Media LLC has been hired for a period beginning on 01/21/2025 and ending on 01/23/2025 to publicly disseminate information about (NTRB:US) via digital communications. To date, including under the previously described agreement, TD Media LLC has been paid two hundred and twenty-five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US).
Please see important disclosure information here: https://lifewatermedia.com/disclosure/ntrb/ | 
No comments:
Post a Comment